Omidenepag

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.^[1][3]

Omidenepag

Clinical data
Trade names	Eybelis, others
Other names	UR-7276, DE-117, Omidenepag isopropyl (JAN JP)
Routes of administration	Topical eye drops
ATC code	S01EX06 (WHO)
Legal status
Legal status	US: ℞-only[1][2] Rx-only[3]
Identifiers
IUPAC name Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
CAS Number	1187451-41-7 1187451-19-9
PubChem CID	44230575 44230999
DrugBank	DB15071
ChemSpider	44210451 57643658
UNII	Z95F9F9LU4 G0G0H52U6K
KEGG	D10965 D10966
ChEMBL	ChEMBL3707245 ChEMBL4297666
Chemical and physical data
Formula	C26H28N6O4S
Molar mass	520.61 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
InChI InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31) Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30) Key:VIQCWEGEHRBLAC-UHFFFAOYSA-N

Omidenepag was approved for medical use in Japan in 2018,^[3] and in the United States in September 2022.^[2][4]

Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.^[1][3]

Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.^[3]

Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.^[5] Omidenepag is a selective prostaglandin E2 receptor agonist.^[6][7]

History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.^[3]